OneSource Specialty Pharma Concludes USFDA Inspection at Sterile Product Division Facility

<h1>OneSource Specialty Pharma Concludes USFDA Inspection at Sterile Product Division Facility</h1>

<p>Onesource Specialty Pharma Limited has received the outcome of a routine Current Good Manufacturing Practices (cGMP) inspection conducted by the United States Food and Drug Administration (USFDA). The inspection focused on the company's Sterile Product Division (SPD) facility located in Bengaluru.</p><p>The audit, which spanned from June 22, 2026, to June 30, 2026, has concluded with one observation. The company is set to comprehensively address this observation and respond to the FDA within the stipulated time frame.</p<p>The inspection details confirm that the USFDA evaluated the manufacturing practices at OneSource Specialty Pharma’s Bengaluru facility, which houses the Sterile Product Division.</p<table border="1" style="width: 100%;">
<thead>
<tr>
<th>Detail</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inspecting Authority</td>
<td>United States Food and Drug Administration (USFDA)</td>
</tr>
<tr>
<td>Facility Audited</td>
<td>Sterile Product Division (SPD) at Bengaluru</td>
</tr>
<tr>
<td>Inspection Period</td>
<td>June 22, 2026 to June 30, 2026</td>
</tr>
<tr>
<td>Outcome Note</td>
<td>One observation recorded</td>
</tr>
</tbody>
</table><p>Management of OneSource Specialty Pharma Limited confirmed that the company will dedicate resources to responding to the single observation in a comprehensive manner as required by regulatory standards.</p>

ONESOURCE Stock Price Movement​

Today, Onesource Specialty Pharma Limited saw its stock climb in the post-market session, closing at ₹1687.60 after gaining 1.81%. The positive move was supported by robust trading, with a total of 156,722 shares changing hands during the day.